Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
Key findingComparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weig
What the researchers found
Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
Why it matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The numbers in context
74.6% of Kuwaiti adults are classified as overweight or obese. Survey conducted February–May 2024 comparing three GLP-1 drugs.
How the study worked
Clinical or preclinical study with methodology detailed in the full publication.
Who was studied
Adults in Kuwait using GLP-1 receptor agonists for weight loss
What this study cannot tell us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
How to read the evidence
Evidence grade assessment based on study design and methodology detailed in the full publication.
When this study was published
Published in 2025. Reflects current state of peptide therapeutic research.
The bigger picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
Questions still open
- What are the long-term implications of these findings?
- How do these results compare to other studies in this area?
- What further research is needed to confirm and extend these findings?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
Frontiers in nutrition, 12, 1590379
Citation
Alali, Saleh; Al-Otaibi, Wed; Ashodian, Karen; Achour, Nour; Almulla, Aishah; Mutlaq, Hessa. (2025). A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.. Frontiers in nutrition, 12, 1590379. https://doi.org/10.3389/fnut.2025.1590379